FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Microbiol Spectr / Dose-Dependent Hepacivirus Infection Reveals Linkage between...
Microbiology spectrum2022; 10(5); e0168622; doi: 10.1128/spectrum.01686-22

Dose-Dependent Hepacivirus Infection Reveals Linkage between Infectious Dose and Immune Response.

Abstract: More than 70 million people worldwide are still infected with the hepatitis C virus 30 years after its discovery, underscoring the need for a vaccine. To develop an effective prophylactic vaccine, detailed knowledge of the correlates of protection and an immunocompetent surrogate model are needed. In this study, we describe the minimum dose required for robust equine hepacivirus (EqHV) infection in equids and examined how this relates to duration of infection, seroconversion, and transcriptomic responses. To investigate mechanisms of hepaciviral persistence, immune response, and immune-mediated pathology, we inoculated eight EqHV naive horses with doses ranging from 1-2 copies to 1.3 × 10 RNA copies per inoculation. We characterized infection kinetics, pathology, and transcriptomic responses via next generation sequencing. The minimal infectious dose of EqHV in horses was estimated at 13 RNA copies, whereas 6 to 7 copies were insufficient to cause infection. Peak viremia did not correlate with infectious dose, while seroconversion and duration of infection appeared to be affected. Notably, seroconversion was undetectable in the low-dose infections within the surveillance period (40 to 50 days). In addition, transcriptomic analysis revealed a nearly dose-dependent effect, with greater immune activation and inflammatory response observed in high-dose infections than in low-dose infections. Interestingly, inoculation with 6-7 copies of RNA that did not result in productive infection, but was associated with a strong immune response, similar to that observed in the high-dose infections. We demonstrate that the EqHV dose of infection plays an important role for inducing immune responses, possibly linked to early clearance in high-dose and prolonged viremia in low-dose infections. In particular, pathways associated with innate and adaptive immune responses, as well as inflammatory responses, were more strongly upregulated in high-dose infections than in lower doses. Hence, inoculation with low doses may enable EqHV to evade strong immune responses in the early phase and therefore promote robust, long-lasting infection.
Get Full Text
Publication Date: 2022-08-22 PubMed ID: 35993785PubMed Central: PMC9602444DOI: 10.1128/spectrum.01686-22Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research study investigates the connection between the dose of equine hepacivirus (EqHV) infection and immune response in horses. The researchers discovered that the level of infection dose plays a crucial role in triggering immune responses, therefore affecting how quickly the infection is cleared or prolonged.

Study Design and Process

  • The researchers inoculated eight horses that had not been previously exposed to EqHV with varying doses – ranging from one to two copies to a high of 1.3 x 10 RNA copies per inoculation.
  • They then monitored the infection kinetics, pathology and responses at the transcriptomic level using next-generation sequencing techniques. The aim was to determine the minimum infectious dose, examine how it related to the duration of infection and seroconversion, and assess the corresponding transcriptomic responses.

Key Findings

  • The researchers estimated that the minimum infectious dose of EqHV in horses was around 13 RNA copies. When less than that, 6-7 RNA copies, were administered, it was insufficient to cause a productive infection.
  • Peak viremia or virus level in blood did not correlate directly with the infectiousness of the dose. However, the process of seroconversion – when the body starts producing detectable antibodies against the virus – and the duration of infection were found to be affected by the dose.
  • In low-dose infections, seroconversion was undetectable within the standard surveillance period of 40-50 days. This significant latency in immune response potentially makes it easier for EqHV to prolong robust and longer-lasting infection in affected animals.
  • On the other hand, high-dose infections witnessed greater immune activation and inflammatory response, which was reflected in the transcriptomic analysis.
  • Interestingly, even doses (6-7 copies) which did not result in a productive infection, triggered a strong immune response, akin to that observed in high-dose infections.

Implications of the Study

  • The study highlights the importance of the dose in hepacivirus infection, showing that it significantly influences the immune response. This could be potentially linked to how quickly the virus is cleared in high-dose infections and why viremia extends for a longer duration in low-dose infections.
  • The clear correlation between dose and various immune response factors could inform the development of vaccinations and treatments for hepacivirus, a global health challenge that remains unsolved.

Cite This Article

APA
Gömer A, Delarocque J, Puff C, Nocke MK, Reinecke B, Baumgärtner W, Cavalleri JMV, Feige K, Steinmann E, Todt D. (2022). Dose-Dependent Hepacivirus Infection Reveals Linkage between Infectious Dose and Immune Response. Microbiol Spectr, 10(5), e0168622. https://doi.org/10.1128/spectrum.01686-22

Publication

Microbiology spectrum
ISSN: 2165-0497
NlmUniqueID: 101634614
Country: United States
Language: English
Volume: 10
Issue: 5
Pages: e0168622
PII: e01686-22

Researcher Affiliations

Gömer, André
  • Department of Molecular and Medical Virology, Ruhr University Bochumgrid.5570.7, Bochum, Germany.
  • Institute of Virology, University of Veterinary Medicine Hannover, Hanover, Germany.
Delarocque, Julien
  • Clinic for Horses, University of Veterinary Medicine Hannover, Hanover, Germany.
Puff, Christina
  • Department of Pathology, University of Veterinary Medicine Hannover, Hanover, Germany.
Nocke, Maximilian K
  • Department of Molecular and Medical Virology, Ruhr University Bochumgrid.5570.7, Bochum, Germany.
Reinecke, Birthe
  • Institute of Experimental Virology, TWINCORE Centre for Experimental and Clinical Infection Research, Hanover, Germany.
Baumgärtner, Wolfgang
  • Department of Pathology, University of Veterinary Medicine Hannover, Hanover, Germany.
Cavalleri, Jessika M V
  • Clinical Section of Equine Internal Medicine, Department of Companion Animals and Horses, University of Veterinary Medicine Viennagrid.6583.8, Vienna, Austria.
Feige, Karsten
  • Clinic for Horses, University of Veterinary Medicine Hannover, Hanover, Germany.
Steinmann, Eike
  • Department of Molecular and Medical Virology, Ruhr University Bochumgrid.5570.7, Bochum, Germany.
Todt, Daniel
  • Department of Molecular and Medical Virology, Ruhr University Bochumgrid.5570.7, Bochum, Germany.
  • European Virus Bioinformatics Center (EVBC), Jena, Germany.

MeSH Terms

  • Horses / genetics
  • Animals
  • Hepacivirus / genetics
  • Viremia
  • Horse Diseases / epidemiology
  • Phylogeny
  • Immunity
  • RNA

Conflict of Interest Statement

The authors declare no conflict of interest.

References

This article includes 58 references
  1. Simmonds P, Becher P, Bukh J, Gould EA, Meyers G, Monath T, Muerhoff S, Pletnev A, Rico-Hesse R, Smith DB, Stapleton JT, Ictv Report Consortium. ICTV Virus Taxonomy Profile: Flaviviridae.. J Gen Virol 2017 Jan;98(1):2-3.
    doi: 10.1099/jgv.0.000672pmc: PMC5370391pubmed: 28218572google scholar: lookup
  2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.. Science 1989 Apr 21;244(4902):359-62.
    doi: 10.1126/science.2523562pubmed: 2523562google scholar: lookup
  3. Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV. Management of acute HCV infection in the era of direct-acting antiviral therapy.. Nat Rev Gastroenterol Hepatol 2018 Jul;15(7):412-424.
    doi: 10.1038/s41575-018-0026-5pubmed: 29773899google scholar: lookup
  4. World Health Organization. Global hepatitis report 2017. 2017.
  5. Bartenschlager R, Lohmann V. Replication of hepatitis C virus.. J Gen Virol 2000 Jul;81(Pt 7):1631-48.
    pubmed: 10859368doi: 10.1099/0022-1317-81-7-1631google scholar: lookup
  6. Martell M, Esteban JI, Quer J, Genescà J, Weiner A, Esteban R, Guardia J, Gómez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.. J Virol 1992 May;66(5):3225-9.
    doi: 10.1128/JVI.66.5.3225-3229.1992pmc: PMC241092pubmed: 1313927google scholar: lookup
  7. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, McKeating JA. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.. Gastroenterology 2007 Feb;132(2):667-78.
    doi: 10.1053/j.gastro.2006.12.008pubmed: 17258731google scholar: lookup
  8. Goffard A, Dubuisson J. Glycosylation of hepatitis C virus envelope proteins.. Biochimie 2003 Mar-Apr;85(3-4):295-301.
    doi: 10.1016/s0300-9084(03)00004-xpubmed: 12770768google scholar: lookup
  9. Lavie M, Hanoulle X, Dubuisson J. Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies.. Front Immunol 2018;9:910.
    doi: 10.3389/fimmu.2018.00910pmc: PMC5934428pubmed: 29755477google scholar: lookup
  10. Prentoe J, Bukh J. Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry.. Front Immunol 2018;9:2146.
    doi: 10.3389/fimmu.2018.02146pmc: PMC6170631pubmed: 30319614google scholar: lookup
  11. Bankwitz D, Doepke M, Hueging K, Weller R, Bruening J, Behrendt P, Lee JY, Vondran FWR, Manns MP, Bartenschlager R, Pietschmann T. Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity.. J Hepatol 2017 Sep;67(3):480-489.
    doi: 10.1016/j.jhep.2017.04.010pubmed: 28438690google scholar: lookup
  12. Fauvelle C, Felmlee DJ, Crouchet E, Lee J, Heydmann L, Lefèvre M, Magri A, Hiet MS, Fofana I, Habersetzer F, Foung SK, Milne R, Patel AH, Vercauteren K, Meuleman P, Zeisel MB, Bartenschlager R, Schuster C, Baumert TF. Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies.. Gastroenterology 2016 Jan;150(1):206-217.e4.
    doi: 10.1053/j.gastro.2015.09.014pubmed: 26404951google scholar: lookup
  13. Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, Alter H, Emerson SU, Cosset FL, Purcell RH, Bukh J. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1.. Proc Natl Acad Sci U S A 2005 Mar 22;102(12):4560-5.
    doi: 10.1073/pnas.0501275102pmc: PMC555507pubmed: 15767578google scholar: lookup
  14. Burm R, Collignon L, Mesalam AA, Meuleman P. Animal Models to Study Hepatitis C Virus Infection.. Front Immunol 2018;9:1032.
    doi: 10.3389/fimmu.2018.01032pmc: PMC5960670pubmed: 29867998google scholar: lookup
  15. Bukh J. Animal models for the study of hepatitis C virus infection and related liver disease.. Gastroenterology 2012 May;142(6):1279-1287.e3.
    doi: 10.1053/j.gastro.2012.02.016pubmed: 22537434google scholar: lookup
  16. Hartlage AS, Cullen JM, Kapoor A. The Strange, Expanding World of Animal Hepaciviruses.. Annu Rev Virol 2016 Sep 29;3(1):53-75.
    doi: 10.1146/annurev-virology-100114-055104pmc: PMC5523456pubmed: 27741408google scholar: lookup
  17. Kapoor A, Simmonds P, Gerold G, Qaisar N, Jain K, Henriquez JA, Firth C, Hirschberg DL, Rice CM, Shields S, Lipkin WI. Characterization of a canine homolog of hepatitis C virus.. Proc Natl Acad Sci U S A 2011 Jul 12;108(28):11608-13.
    doi: 10.1073/pnas.1101794108pmc: PMC3136326pubmed: 21610165google scholar: lookup
  18. Pfaender S, Cavalleri JM, Walter S, Doerrbecker J, Campana B, Brown RJ, Burbelo PD, Postel A, Hahn K, Anggakusuma, Riebesehl N, Baumgärtner W, Becher P, Heim MH, Pietschmann T, Feige K, Steinmann E. Clinical course of infection and viral tissue tropism of hepatitis C virus-like nonprimate hepaciviruses in horses.. Hepatology 2015 Feb;61(2):447-59.
    doi: 10.1002/hep.27440pubmed: 25212983google scholar: lookup
  19. Pfaender S, Walter S, Grabski E, Todt D, Bruening J, Romero-Brey I, Gather T, Brown RJ, Hahn K, Puff C, Pfankuche VM, Hansmann F, Postel A, Becher P, Thiel V, Kalinke U, Wagner B, Bartenschlager R, Baumgärtner W, Feige K, Pietschmann T, Cavalleri JM, Steinmann E. Immune protection against reinfection with nonprimate hepacivirus.. Proc Natl Acad Sci U S A 2017 Mar 21;114(12):E2430-E2439.
    doi: 10.1073/pnas.1619380114pmc: PMC5373355pubmed: 28275093google scholar: lookup
  20. Ramsay JD, Evanoff R, Wilkinson TE Jr, Divers TJ, Knowles DP, Mealey RH. Experimental transmission of equine hepacivirus in horses as a model for hepatitis C virus.. Hepatology 2015 May;61(5):1533-46.
    doi: 10.1002/hep.27689pubmed: 25580897google scholar: lookup
  21. Tegtmeyer B, Echelmeyer J, Pfankuche VM, Puff C, Todt D, Fischer N, Durham A, Feige K, Baumgärtner W, Steinmann E, Cavalleri JV. Chronic equine hepacivirus infection in an adult gelding with severe hepatopathy.. Vet Med Sci 2019 Aug;5(3):372-378.
    doi: 10.1002/vms3.181pmc: PMC6682795pubmed: 31267690google scholar: lookup
  22. Gather T, Walter S, Pfaender S, Todt D, Feige K, Steinmann E, Cavalleri JM. Acute and chronic infections with nonprimate hepacivirus in young horses.. Vet Res 2016 Sep 22;47(1):97.
    doi: 10.1186/s13567-016-0381-6pmc: PMC5034468pubmed: 27659317google scholar: lookup
  23. Tanaka T, Kasai H, Yamashita A, Okuyama-Dobashi K, Yasumoto J, Maekawa S, Enomoto N, Okamoto T, Matsuura Y, Morimatsu M, Manabe N, Ochiai K, Yamashita K, Moriishi K. Hallmarks of hepatitis C virus in equine hepacivirus.. J Virol 2014 Nov;88(22):13352-66.
    doi: 10.1128/JVI.02280-14pmc: PMC4249100pubmed: 25210167google scholar: lookup
  24. Yu Y, Scheel TKH, Luna JM, Chung H, Nishiuchi E, Scull MA, Echeverría N, Ricardo-Lax I, Kapoor A, Lipkin WI, Divers TJ, Antczak DF, Tennant BC, Rice CM. miRNA independent hepacivirus variants suggest a strong evolutionary pressure to maintain miR-122 dependence.. PLoS Pathog 2017 Oct;13(10):e1006694.
    doi: 10.1371/journal.ppat.1006694pmc: PMC5679655pubmed: 29084265google scholar: lookup
  25. Scheel TK, Kapoor A, Nishiuchi E, Brock KV, Yu Y, Andrus L, Gu M, Renshaw RW, Dubovi EJ, McDonough SP, Van de Walle GR, Lipkin WI, Divers TJ, Tennant BC, Rice CM. Characterization of nonprimate hepacivirus and construction of a functional molecular clone.. Proc Natl Acad Sci U S A 2015 Feb 17;112(7):2192-7.
    doi: 10.1073/pnas.1500265112pmc: PMC4343093pubmed: 25646476google scholar: lookup
  26. Tomlinson JE, Wolfisberg R, Fahnøe U, Patel RS, Trivedi S, Kumar A, Sharma H, Nielsen L, McDonough SP, Bukh J, Tennant BC, Kapoor A, Rosenberg BR, Rice CM, Divers TJ, Van de Walle GR, Scheel TKH. Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection.. Hepatology 2021 Sep;74(3):1148-1163.
    doi: 10.1002/hep.31802pmc: PMC8435542pubmed: 33713356google scholar: lookup
  27. Burbelo PD, Dubovi EJ, Simmonds P, Medina JL, Henriquez JA, Mishra N, Wagner J, Tokarz R, Cullen JM, Iadarola MJ, Rice CM, Lipkin WI, Kapoor A. Serology-enabled discovery of genetically diverse hepaciviruses in a new host.. J Virol 2012 Jun;86(11):6171-8.
    doi: 10.1128/JVI.00250-12pmc: PMC3372197pubmed: 22491452google scholar: lookup
  28. Walter S, Rasche A, Moreira-Soto A, Pfaender S, Bletsa M, Corman VM, Aguilar-Setien A, García-Lacy F, Hans A, Todt D, Schuler G, Shnaiderman-Torban A, Steinman A, Roncoroni C, Veneziano V, Rusenova N, Sandev N, Rusenov A, Zapryanova D, García-Bocanegra I, Jores J, Carluccio A, Veronesi MC, Cavalleri JMV, Drosten C, Lemey P, Steinmann E, Drexler JF. Differential Infection Patterns and Recent Evolutionary Origins of Equine Hepaciviruses in Donkeys.. J Virol 2017 Jan 1;91(1).
    doi: 10.1128/JVI.01711-16pmc: PMC5165184pubmed: 27795428google scholar: lookup
  29. Lyons S, Kapoor A, Schneider BS, Wolfe ND, Culshaw G, Corcoran B, Durham AE, Burden F, McGorum BC, Simmonds P. Viraemic frequencies and seroprevalence of non-primate hepacivirus and equine pegiviruses in horses and other mammalian species.. J Gen Virol 2014 Aug;95(Pt 8):1701-1711.
    doi: 10.1099/vir.0.065094-0pubmed: 24814924google scholar: lookup
  30. Reichert C, Campe A, Walter S, Pfaender S, Welsch K, Ruddat I, Sieme H, Feige K, Steinmann E, Cavalleri JMV. Frequent occurrence of nonprimate hepacivirus infections in Thoroughbred breeding horses - A cross-sectional study for the occurrence of infections and potential risk factors.. Vet Microbiol 2017 May;203:315-322.
    doi: 10.1016/j.vetmic.2017.03.030pubmed: 28619163google scholar: lookup
  31. Lu G, Sun L, Xu T, He D, Wang Z, Ou S, Jia K, Yuan L, Li S. First Description of Hepacivirus and Pegivirus Infection in Domestic Horses in China: A Study in Guangdong Province, Heilongjiang Province and Hong Kong District.. PLoS One 2016;11(5):e0155662.
    doi: 10.1371/journal.pone.0155662pmc: PMC4868292pubmed: 27182887google scholar: lookup
  32. Gömer A, Puff C, Reinecke B, Bracht S, Conze M, Baumgärtner W, Steinmann J, Feige K, Cavalleri JMV, Steinmann E, Todt D. Experimental cross-species infection of donkeys with equine hepacivirus and analysis of host immune signatures.. One Health Outlook 2022 May 9;4(1):9.
    doi: 10.1186/s42522-022-00065-ypmc: PMC9082851pubmed: 35527255google scholar: lookup
  33. Boldanova T, Suslov A, Heim MH, Necsulea A. Transcriptional response to hepatitis C virus infection and interferon-alpha treatment in the human liver.. EMBO Mol Med 2017 Jun;9(6):816-834.
    doi: 10.15252/emmm.201607006pmc: PMC5452008pubmed: 28360091google scholar: lookup
  34. Yan Z, Wang Y. Viral and host factors associated with outcomes of hepatitis C virus infection (Review).. Mol Med Rep 2017 May;15(5):2909-2924.
    doi: 10.3892/mmr.2017.6351pubmed: 28339063google scholar: lookup
  35. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.. Science 2000 Apr 14;288(5464):339-44.
    doi: 10.1126/science.288.5464.339pubmed: 10764648google scholar: lookup
  36. Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission.. Hepatology 1998 Aug;28(2):562-7.
    doi: 10.1002/hep.510280238pubmed: 9696025google scholar: lookup
  37. Gömer A, Brown RJP, Pfaender S, Deterding K, Reuter G, Orton R, Seitz S, Bock CT, Cavalleri JMV, Pietschmann T, Wedemeyer H, Steinmann E, Todt D. Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance.. Virus Evol 2022;8(1):veac007.
    doi: 10.1093/ve/veac007pmc: PMC8887644pubmed: 35242360google scholar: lookup
  38. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection.. J Exp Med 2001 Nov 19;194(10):1395-406.
    doi: 10.1084/jem.194.10.1395pmc: PMC2193681pubmed: 11714747google scholar: lookup
  39. Kubitschke A, Bahr MJ, Aslan N, Bader C, Tillmann HL, Sarrazin C, Greten T, Wiegand J, Manns MP, Wedemeyer H. Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia.. Eur J Clin Invest 2007 Jan;37(1):54-64.
    doi: 10.1111/j.1365-2362.2007.01753.xpubmed: 17181568google scholar: lookup
  40. Sulkowski MS, Ray SC, Thomas DL. Needlestick transmission of hepatitis C.. JAMA 2002 May 8;287(18):2406-13.
    doi: 10.1001/jama.287.18.2406pubmed: 11988061google scholar: lookup
  41. Shata MT, Tricoche N, Perkus M, Tom D, Brotman B, McCormack P, Pfahler W, Lee DH, Tobler LH, Busch M, Prince AM. Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees.. Virology 2003 Sep 30;314(2):601-16.
    doi: 10.1016/s0042-6822(03)00461-6pmc: PMC3898342pubmed: 14554088google scholar: lookup
  42. Katayama K, Kumagai J, Komiya Y, Mizui M, Yugi H, Kishimoto S, Yamanaka R, Tamatsukuri S, Tomoguri T, Miyakawa Y, Tanaka J, Yoshizawa H. Titration of hepatitis C virus in chimpanzees for determining the copy number required for transmission.. Intervirology 2004;47(1):57-64.
    doi: 10.1159/000076643pubmed: 15044837google scholar: lookup
  43. Billerbeck E, Wolfisberg R, Fahnøe U, Xiao JW, Quirk C, Luna JM, Cullen JM, Hartlage AS, Chiriboga L, Ghoshal K, Lipkin WI, Bukh J, Scheel TKH, Kapoor A, Rice CM. Mouse models of acute and chronic hepacivirus infection.. Science 2017 Jul 14;357(6347):204-208.
    doi: 10.1126/science.aal1962pmc: PMC5654634pubmed: 28706073google scholar: lookup
  44. Major ME, Dahari H, Mihalik K, Puig M, Rice CM, Neumann AU, Feinstone SM. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees.. Hepatology 2004 Jun;39(6):1709-20.
    doi: 10.1002/hep.20239pubmed: 15185313google scholar: lookup
  45. Bukh J. A critical role for the chimpanzee model in the study of hepatitis C.. Hepatology 2004 Jun;39(6):1469-75.
    doi: 10.1002/hep.20268pubmed: 15185284google scholar: lookup
  46. Park SH, Veerapu NS, Shin EC, Biancotto A, McCoy JP, Capone S, Folgori A, Rehermann B. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection.. Nat Med 2013 Dec;19(12):1638-42.
    doi: 10.1038/nm.3408pmc: PMC4196667pubmed: 24270546google scholar: lookup
  47. Abdelwahab SF. Cellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important?. Infect Agent Cancer 2016;11:23.
    doi: 10.1186/s13027-016-0070-0pmc: PMC4867533pubmed: 27186234google scholar: lookup
  48. Bassett SE, Brasky KM, Lanford RE. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles.. J Virol 1998 Apr;72(4):2589-99.
    doi: 10.1128/JVI.72.4.2589-2599.1998pmc: PMC109692pubmed: 9525575google scholar: lookup
  49. Thomson M, Nascimbeni M, Havert MB, Major M, Gonzales S, Alter H, Feinstone SM, Murthy KK, Rehermann B, Liang TJ. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity.. J Virol 2003 Jan;77(2):862-70.
    doi: 10.1128/jvi.77.2.862-870.2003pmc: PMC140840pubmed: 12502802google scholar: lookup
  50. Bukh J, Wantzin P, Krogsgaard K, Knudsen F, Purcell RH, Miller RH. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group.. J Infect Dis 1993 Dec;168(6):1343-8.
    doi: 10.1093/infdis/168.6.1343pubmed: 7504031google scholar: lookup
  51. Meyer MF, Lehmann M, Cornberg M, Wiegand J, Manns MP, Klade C, Wedemeyer H. Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response.. Virol J 2007 Jun 11;4:58.
    doi: 10.1186/1743-422X-4-58pmc: PMC1914341pubmed: 17562015google scholar: lookup
  52. Kao JH, Lai MY, Hwang YT, Yang PM, Chen PJ, Sheu JC, Wang TH, Hsu HC, Chen DS. Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay. A clinicopathologic study and demonstration of the usefulness of a third-generation assay.. Dig Dis Sci 1996 Jan;41(1):161-5.
    doi: 10.1007/BF02208599pubmed: 8565750google scholar: lookup
  53. Sallie R, King R, Silva E, Tibbs C, Johnson P, Williams R. Community prevalence of hepatitis C viraemia: a polymerase chain reaction study.. J Med Virol 1994 Jun;43(2):111-4.
    doi: 10.1002/jmv.1890430202pubmed: 8083657google scholar: lookup
  54. Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, Haber PS, Marinos G, Levy MH, Kaldor JM, Dolan KA, Ffrench RA, Lloyd AR, Rawlinson WD. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort.. J Infect Dis 2004 May 15;189(10):1846-55.
    doi: 10.1086/383279pubmed: 15122521google scholar: lookup
  55. Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses.. Immunity 2014 Jan 16;40(1):13-24.
    doi: 10.1016/j.immuni.2013.12.010pmc: PMC4480226pubmed: 24439265google scholar: lookup
  56. Abdel-Hakeem MS, Shoukry NH. Protective immunity against hepatitis C: many shades of gray.. Front Immunol 2014;5:274.
    doi: 10.3389/fimmu.2014.00274pmc: PMC4058636pubmed: 24982656google scholar: lookup
  57. Tegtmeyer B, Vieyres G, Todt D, Lauber C, Ginkel C, Engelmann M, Herrmann M, Pfaller CK, Vondran FWR, Broering R, Vafadarnejad E, Saliba AE, Puff C, Baumgärtner W, Miskey C, Ivics Z, Steinmann E, Pietschmann T, Brown RJP. Initial HCV infection of adult hepatocytes triggers a temporally structured transcriptional program containing diverse pro- and anti-viral elements.. J Virol 2021 Apr 26;95(10).
    doi: 10.1128/JVI.00245-21pmc: PMC8139656pubmed: 33658347google scholar: lookup
  58. Rosenberg BR, Depla M, Freije CA, Gaucher D, Mazouz S, Boisvert M, Bédard N, Bruneau J, Rice CM, Shoukry NH. Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance.. PLoS Pathog 2018 Sep;14(9):e1007290.
    doi: 10.1371/journal.ppat.1007290pmc: PMC6160227pubmed: 30222771google scholar: lookup

Citations

This article has been cited 3 times.
  1. Wolfisberg R, Holmbeck K, Billerbeck E, Thorselius CE, Batista MN, Fahnøe U, Lundsgaard EA, Kennedy MJ, Nielsen L, Rice CM, Bukh J, Scheel TKH. Molecular Determinants of Mouse Adaptation of Rat Hepacivirus. J Virol 2023 Apr 27;97(4):e0181222.
    doi: 10.1128/jvi.01812-22pubmed: 36971565google scholar: lookup
  2. Frisch V, Ramsauer AS, Preining I, Unterköfler MS, Fuehrer HP, Hofer M, Lyrakis M, Bouhsira E, Liénard E, Cavalleri JV. First detection of equine hepacivirus RNA in Stomoxys calcitrans (Diptera, Muscidae) in eastern Austria. BMC Vet Res 2025 Jul 17;21(1):474.
    doi: 10.1186/s12917-025-04890-xpubmed: 40676642google scholar: lookup
  3. Wu H, Wang X, Kong X, Shan R, Peng S, Zhao M, Chen C, Yu W, Li Z. Genomic Characterization and Functional Evaluation of Eurotium cristatum EC-520: Impacts on Colon Barrier Integrity, Gut Microbiota, and Metabolite Profile in Rats. Foods 2025 Apr 29;14(9).
    doi: 10.3390/foods14091569pubmed: 40361651google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.